nicardipine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
calcium channel blockers, nifedipine derivatives	1909	55985-32-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: nicardipine (+/-)-Nicardipine perpidine nicardipine hydrochloride nicardipine HCl	A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents. Molecular weight: 479.53 Formula: C26H29N3O6 CLOGP: 5.23 LIPINSKI: 1 HAC: 9 HDO: 1 TPSA: 111.01 ALOGS: -5.29 ROTB: 11 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

nicardipine
(+/-)-Nicardipine
perpidine
nicardipine hydrochloride
nicardipine HCl

A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents.

Molecular weight: 479.53
Formula: C26H29N3O6
CLOGP: 5.23
LIPINSKI: 1
HAC: 9
HDO: 1
TPSA: 111.01
ALOGS: -5.29
ROTB: 11

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
90	mg	O
90	mg	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	7.90 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	4.17 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	23 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	1 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	11 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.01 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	4.10 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Dec. 21, 1988	FDA	CHIESI USA INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Premature delivery	172.76	24.01	78	6808	30203	63451933
Acute kidney injury	140.29	24.01	157	6729	263258	63218878
Cerebral vasoconstriction	138.66	24.01	31	6855	1177	63480959
Hyponatraemia	127.86	24.01	102	6784	111798	63370338
Eosinophilia	106.09	24.01	51	6835	22705	63459431
Posterior reversible encephalopathy syndrome	99.88	24.01	45	6841	17300	63464836
Hyperkalaemia	97.33	24.01	65	6821	54138	63427998
Hepatocellular injury	94.31	24.01	50	6836	27331	63454805
Acute motor-sensory axonal neuropathy	83.82	24.01	16	6870	273	63481863
Hypotension	81.11	24.01	122	6764	272482	63209654
Cerebral haemorrhage	80.85	24.01	47	6839	30682	63451454
Acute pulmonary oedema	80.20	24.01	31	6855	8127	63474009
Exposure during pregnancy	79.63	24.01	91	6795	155456	63326680
Premature baby	74.62	24.01	39	6847	20696	63461440
Low birth weight baby	73.33	24.01	28	6858	7101	63475035
Cholestasis	69.53	24.01	42	6844	29392	63452744
Drug reaction with eosinophilia and systemic symptoms	61.72	24.01	41	6845	33795	63448341
Bradycardia	61.49	24.01	56	6830	73171	63408965
Rash maculo-papular	59.03	24.01	39	6847	31857	63450279
Lactic acidosis	57.14	24.01	41	6845	38246	63443890
Maternal exposure during pregnancy	56.34	24.01	92	6794	219970	63262166
Hyperlactacidaemia	55.50	24.01	18	6868	2831	63479305
Acute generalised exanthematous pustulosis	55.14	24.01	26	6860	11073	63471063
Hepatic cytolysis	49.84	24.01	27	6859	15380	63466756
Hemivertebra	49.22	24.01	9	6877	120	63482016
Subarachnoid haemorrhage	48.92	24.01	26	6860	14257	63467879
Haemangioma congenital	48.61	24.01	11	6875	441	63481695
Orthostatic hypotension	47.81	24.01	36	6850	36124	63446012
Foetal exposure during pregnancy	47.16	24.01	34	6852	31928	63450208
Fatigue	46.91	24.01	19	6867	888009	62594127
Haemorrhagic transformation stroke	46.62	24.01	13	6873	1222	63480914
Drug interaction	45.89	24.01	86	6800	229045	63253091
Fall	45.32	24.01	118	6768	392216	63089920
Thrombocytopenia	45.32	24.01	68	6818	151089	63331047
Foetal growth restriction	44.75	24.01	20	6866	7533	63474603
Hypokalaemia	43.64	24.01	55	6831	103749	63378387
Purpura	42.63	24.01	22	6864	11363	63470773
Rash pustular	42.24	24.01	19	6867	7263	63474873
Congenital choroid plexus cyst	40.92	24.01	9	6877	316	63481820
Pain	40.47	24.01	15	6871	740613	62741523
Renal failure	39.72	24.01	56	6830	117596	63364540
Ischaemic stroke	38.26	24.01	24	6862	17933	63464203
Paradoxical drug reaction	38.05	24.01	15	6871	4137	63477999
Haemodynamic instability	38.03	24.01	19	6867	9171	63472965
Premature labour	37.92	24.01	21	6865	12483	63469653
Arthralgia	37.65	24.01	8	6878	569702	62912434
Rhabdomyolysis	37.63	24.01	34	6852	43917	63438219
Toxic skin eruption	37.33	24.01	21	6865	12864	63469272
Haematoma	36.00	24.01	30	6856	34790	63447346
Pre-eclampsia	35.21	24.01	18	6868	9115	63473021
Metabolic encephalopathy	33.20	24.01	15	6871	5794	63476342
Delayed ischaemic neurological deficit	32.52	24.01	4	6882	0	63482136
Anaphylactic shock	32.28	24.01	24	6862	23609	63458527
Patent ductus arteriosus	30.89	24.01	13	6873	4237	63477899
Altered state of consciousness	30.88	24.01	24	6862	25206	63456930
Mixed liver injury	29.53	24.01	13	6873	4722	63477414
Cutaneous lupus erythematosus	29.14	24.01	11	6875	2701	63479435
Respiratory distress	28.54	24.01	26	6860	33925	63448211
Tumour rupture	28.49	24.01	6	6880	171	63481965
Cardiac arrest	28.23	24.01	42	6844	92503	63389633
Hypertrophic cardiomyopathy	26.79	24.01	9	6877	1578	63480558
Acquired haemophilia	26.28	24.01	8	6878	1023	63481113
Intra-abdominal haematoma	25.65	24.01	9	6877	1796	63480340
Sinus bradycardia	25.00	24.01	17	6869	14534	63467602
Metabolic acidosis	24.07	24.01	27	6859	45042	63437094

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cerebral vasoconstriction	107.21	21.17	20	4812	231	34951868
Blood lactic acid	88.83	21.17	18	4814	328	34951771
Foetal disorder	83.47	21.17	20	4812	806	34951293
Premature baby	81.47	21.17	44	4788	19589	34932510
Neutropenia neonatal	75.89	21.17	18	4814	694	34951405
Acute kidney injury	66.37	21.17	136	4696	304852	34647247
Eosinophilia	64.67	21.17	42	4790	26180	34925919
Low birth weight baby	63.99	21.17	28	4804	7877	34944222
Ureteric compression	62.67	21.17	13	4819	267	34951832
Cerebral haemorrhage	58.21	21.17	44	4788	34893	34917206
Rash maculo-papular	54.54	21.17	39	4793	28412	34923687
Pyelocaliectasis	44.65	21.17	13	4819	1117	34950982
Foetal exposure during pregnancy	44.47	21.17	39	4793	38062	34914037
Antiphospholipid antibodies positive	44.26	21.17	10	4822	310	34951789
Haematoma muscle	42.20	21.17	13	4819	1355	34950744
Cholestasis	36.38	21.17	30	4802	26918	34925181
Drug reaction with eosinophilia and systemic symptoms	33.03	21.17	31	4801	32981	34919118
Phlebitis deep	32.51	21.17	5	4827	15	34952084
Hypertensive crisis	31.84	21.17	18	4814	8733	34943366
Bradycardia	31.36	21.17	45	4787	75373	34876726
Extravasation	30.42	21.17	11	4821	1879	34950220
Hepatic cytolysis	30.38	21.17	21	4811	14475	34937624
Haemorrhagic transformation stroke	28.83	21.17	10	4822	1513	34950586
Thalamus haemorrhage	28.69	21.17	9	4823	996	34951103
Hyperkalaemia	28.26	21.17	41	4791	69348	34882751
Paradoxical drug reaction	27.53	21.17	12	4820	3339	34948760
Kidney small	26.62	21.17	5	4827	60	34952039
Haemolytic anaemia	26.34	21.17	17	4815	10462	34941637
Brain herniation	25.47	21.17	12	4820	3996	34948103
Hepatocellular injury	22.48	21.17	21	4811	22190	34929909
Haemorrhagic cerebral infarction	21.57	21.17	7	4825	864	34951235
Respiratory gas exchange disorder	21.20	21.17	6	4826	466	34951633

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cerebral vasoconstriction	230.24	19.92	51	11163	1419	79731755
Acute kidney injury	183.64	19.92	289	10925	519115	79214059
Eosinophilia	162.95	19.92	93	11121	45252	79687922
Cerebral haemorrhage	120.73	19.92	84	11130	57589	79675585
Hyperkalaemia	104.67	19.92	103	11111	114295	79618879
Rash maculo-papular	102.02	19.92	75	11139	56003	79677171
Hepatocellular injury	98.85	19.92	69	11145	47524	79685650
Cholestasis	97.75	19.92	71	11143	52038	79681136
Hyponatraemia	92.03	19.92	119	11095	177729	79555445
Premature delivery	89.30	19.92	50	11164	23417	79709757
Blood lactic acid	83.28	19.92	18	11196	445	79732729
Drug reaction with eosinophilia and systemic symptoms	82.52	19.92	70	11144	64174	79669000
Posterior reversible encephalopathy syndrome	81.44	19.92	49	11165	26232	79706942
Hepatic cytolysis	77.42	19.92	48	11166	27103	79706071
Bradycardia	73.70	19.92	93	11121	135464	79597710
Acute motor-sensory axonal neuropathy	73.36	19.92	16	11198	413	79732761
Haemorrhagic transformation stroke	67.77	19.92	22	11192	2670	79730504
Paradoxical drug reaction	62.75	19.92	27	11187	7158	79726016
Ureteric compression	62.30	19.92	13	11201	270	79732904
Hypotension	62.11	19.92	168	11046	440149	79293025
Acute pulmonary oedema	58.75	19.92	32	11182	14198	79718976
Fatigue	57.04	19.92	30	11184	929697	78803477
Exposure during pregnancy	54.33	19.92	69	11145	101063	79632111
Hypokalaemia	50.30	19.92	80	11134	143960	79589214
Lactic acidosis	49.33	19.92	55	11159	70304	79662870
Pyelocaliectasis	46.89	19.92	13	11201	920	79732254
Pain	45.69	19.92	21	11193	703781	79029393
Acute generalised exanthematous pustulosis	45.40	19.92	29	11185	17225	79715949
Renal failure	45.03	19.92	92	11122	200876	79532298
Altered state of consciousness	44.83	19.92	42	11172	43780	79689394
Ischaemic stroke	44.37	19.92	37	11177	33094	79700080
Haematoma	44.00	19.92	45	11169	52150	79681024
Subarachnoid haemorrhage	42.84	19.92	32	11182	24433	79708741
Rash pustular	42.75	19.92	24	11190	11287	79721887
Mixed liver injury	42.68	19.92	21	11193	7557	79725617
Hyperlactacidaemia	42.30	19.92	19	11195	5576	79727598
Purpura	42.13	19.92	29	11185	19498	79713676
Respiratory distress	38.16	19.92	44	11170	58295	79674879
Thrombocytopenia	37.09	19.92	101	11113	265158	79468016
Delayed ischaemic neurological deficit	37.00	19.92	5	11209	3	79733171
Orthostatic hypotension	36.13	19.92	42	11172	56122	79677052
Hypertensive crisis	35.99	19.92	27	11187	20743	79712431
Cardiac arrest	35.29	19.92	76	11138	172020	79561154
Fall	33.94	19.92	147	11067	487482	79245692
Haematoma muscle	33.72	19.92	13	11201	2602	79730572
Maternal exposure during pregnancy	33.56	19.92	65	11149	136473	79596701
Drug interaction	32.68	19.92	130	11084	415053	79318121
Pre-eclampsia	32.34	19.92	17	11197	7024	79726150
Premature labour	32.24	19.92	18	11196	8372	79724802
Phlebitis deep	31.51	19.92	5	11209	19	79733155
Brain herniation	31.40	19.92	17	11197	7446	79725728
Confusional state	31.24	19.92	107	11107	317890	79415284
Antiphospholipid antibodies positive	30.92	19.92	9	11205	759	79732415
Haemolytic anaemia	30.51	19.92	23	11191	17797	79715377
Toxic skin eruption	30.06	19.92	25	11189	22268	79710906
Haemorrhagic cerebral infarction	28.94	19.92	10	11204	1469	79731705
Thalamus haemorrhage	27.12	19.92	10	11204	1772	79731402
Pulmonary hypoplasia	27.02	19.92	5	11209	54	79733120
Haemodynamic instability	26.63	19.92	21	11193	17361	79715813
Thrombotic microangiopathy	25.92	19.92	22	11192	20147	79713027
Dizziness	25.46	19.92	22	11192	526419	79206755
Cutaneous lupus erythematosus	25.29	19.92	11	11203	2992	79730182
Rhabdomyolysis	25.21	19.92	49	11165	103082	79630092
Anaphylactic shock	24.98	19.92	28	11186	35968	79697206
Peripheral swelling	24.97	19.92	4	11210	269613	79463561
Metabolic acidosis	24.97	19.92	43	11171	82486	79650688
Abdominal discomfort	24.91	19.92	3	11211	250724	79482450
Agranulocytosis	24.60	19.92	31	11183	44999	79688175
Drug intolerance	24.28	19.92	4	11210	264115	79469059
Cerebral infarction	24.25	19.92	31	11183	45645	79687529
Arthralgia	24.07	19.92	27	11187	571776	79161398
Angioedema	23.51	19.92	40	11174	75995	79657179
Vasoplegia syndrome	23.29	19.92	11	11203	3619	79729555
Metabolic encephalopathy	23.14	19.92	15	11199	9132	79724042
Gestational hypertension	23.02	19.92	9	11205	1870	79731304
Acquired haemophilia	22.87	19.92	9	11205	1902	79731272
Alopecia	22.42	19.92	3	11211	231352	79501822
Weight decreased	22.37	19.92	11	11203	355187	79377987
Headache	22.32	19.92	36	11178	653736	79079438
Brain contusion	21.99	19.92	8	11206	1365	79731809
Foetal growth restriction	21.97	19.92	9	11205	2110	79731064
Hypertrophic cardiomyopathy	21.11	19.92	9	11205	2331	79730843
Dyspnoea	21.02	19.92	57	11157	856968	78876206
Tumour rupture	21.01	19.92	6	11208	473	79732701
Nasopharyngitis	20.92	19.92	5	11209	253876	79479298
Drug hypersensitivity	20.81	19.92	8	11206	298908	79434266
Porphyria	20.74	19.92	5	11209	203	79732971
Shock	20.71	19.92	28	11186	43520	79689654
Cerebral haematoma	20.03	19.92	13	11201	7929	79725245
Ventricular tachycardia	19.99	19.92	27	11187	41908	79691266

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C08CA04	CARDIOVASCULAR SYSTEM CALCIUM CHANNEL BLOCKERS SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS Dihydropyridine derivatives
FDA CS	M0006414	Dihydropyridines
FDA MoA	N0000000069	Calcium Channel Antagonists
FDA EPC	N0000175421	Dihydropyridine Calcium Channel Blocker
MeSH PA	D000959	Antihypertensive Agents
MeSH PA	D002121	Calcium Channel Blockers
MeSH PA	D000077264	Calcium-Regulating Hormones and Agents
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D049990	Membrane Transport Modulators
MeSH PA	D014665	Vasodilator Agents
CHEBI has role	CHEBI:35620	vasodilator agents
CHEBI has role	CHEBI:35674	antihypertensive drugs
CHEBI has role	CHEBI:38215	calcium channel blockers
CHEBI has role	CHEBI:88230	autophagy inhibitors
CHEBI has role	CHEBI:176497	geroprotectors
FDA MoA	N0000182137	Cytochrome P450 2D6 Inhibitors
FDA MoA	N0000182140	Cytochrome P450 2C19 Inhibitors
FDA MoA	N0000182141	Cytochrome P450 3A4 Inhibitors
FDA MoA	N0000187062	Cytochrome P450 2C8 Inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hypertensive disorder	indication	38341003	DOID:10763
Angina pectoris	indication	194828000
Prinzmetal angina	off-label use	87343002
Raynaud's phenomenon	off-label use	266261006
Portal hypertension	contraindication	34742003	DOID:10762
Low blood pressure	contraindication	45007003
Chronic heart failure	contraindication	48447003
Chronic idiopathic constipation	contraindication	82934008
Impaired renal function disorder	contraindication	197663003
Disease of liver	contraindication	235856003	DOID:409
Cerebral hemorrhage	contraindication	274100004
Cerebral infarction	contraindication	432504007	DOID:3526
Severe Aortic Valve Stenosis	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	7.02	Basic
pKa2	2.37	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
20MG/200ML (0.1MG/ML)	CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER	CHIESI	N019734	July 31, 2008	RX	INJECTABLE	INTRAVENOUS	11547758	April 18, 2027	METHOD FOR TREATING ACUTE ELEVATIONS OF BLOOD PRESSURE IN HUMAN SUBJECT IN NEED THEREOF
20MG/200ML (0.1MG/ML)	CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER	CHIESI	N019734	July 31, 2008	RX	INJECTABLE	INTRAVENOUS	11547758	April 18, 2027	METHOD FOR TREATING ACUTE ELEVATIONS OF BLOOD PRESSURE IN HUMAN SUBJECT IN NEED THEREOF
20MG/200ML (0.1MG/ML)	CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER	CHIESI	N019734	July 31, 2008	RX	INJECTABLE	INTRAVENOUS	7659291	April 18, 2027	METHOD FOR TREATING ACUTE ELEVATIONS OF BLOOD PRESSURE IN HUMAN SUBJECT IN NEED THEREOF
20MG/200ML (0.1MG/ML)	CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER	CHIESI	N019734	July 31, 2008	RX	INJECTABLE	INTRAVENOUS	7659291	April 18, 2027	METHOD FOR TREATING ACUTE ELEVATIONS OF BLOOD PRESSURE IN HUMAN SUBJECT IN NEED THEREOF
20MG/200ML (0.1MG/ML)	CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER	CHIESI	N019734	July 31, 2008	RX	INJECTABLE	INTRAVENOUS	8455524	April 18, 2027	METHOD FOR TREATING ACUTE ELEVATIONS OF BLOOD PRESSURE IN HUMAN SUBJECT IN NEED THEREOF
20MG/200ML (0.1MG/ML)	CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER	CHIESI	N019734	July 31, 2008	RX	INJECTABLE	INTRAVENOUS	8455524	April 18, 2027	METHOD FOR TREATING ACUTE ELEVATIONS OF BLOOD PRESSURE IN HUMAN SUBJECT IN NEED THEREOF
40MG/200ML (0.2MG/ML)	CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER	CHIESI	N019734	Nov. 7, 2008	RX	INJECTABLE	INTRAVENOUS	11547758	April 18, 2027	METHOD FOR TREATING ACUTE ELEVATIONS OF BLOOD PRESSURE IN HUMAN SUBJECT IN NEED THEREOF
40MG/200ML (0.2MG/ML)	CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER	CHIESI	N019734	Nov. 7, 2008	RX	INJECTABLE	INTRAVENOUS	7659291	April 18, 2027	METHOD FOR TREATING ACUTE ELEVATIONS OF BLOOD PRESSURE IN HUMAN SUBJECT IN NEED THEREOF
40MG/200ML (0.2MG/ML)	CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER	CHIESI	N019734	Nov. 7, 2008	DISCN	INJECTABLE	INTRAVENOUS	7659291	April 18, 2027	METHOD FOR TREATING ACUTE ELEVATIONS OF BLOOD PRESSURE IN HUMAN SUBJECT IN NEED THEREOF
40MG/200ML (0.2MG/ML)	CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER	CHIESI	N019734	Nov. 7, 2008	RX	INJECTABLE	INTRAVENOUS	8455524	April 18, 2027	METHOD FOR TREATING ACUTE ELEVATIONS OF BLOOD PRESSURE IN HUMAN SUBJECT IN NEED THEREOF
40MG/200ML (0.2MG/ML)	CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER	CHIESI	N019734	Nov. 7, 2008	DISCN	INJECTABLE	INTRAVENOUS	8455524	April 18, 2027	METHOD FOR TREATING ACUTE ELEVATIONS OF BLOOD PRESSURE IN HUMAN SUBJECT IN NEED THEREOF

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Voltage-gated L-type calcium channel	Ion channel	Q01668 Q13936	CAC1D_HUMAN CAC1C_HUMAN	BLOCKER			CHEMBL	CHEMBL
Multidrug resistance protein 1	Transporter	P08183	MDR1_HUMAN		IC50	5.32	CHEMBL
Adenosine receptor A3	GPCR	P0DMS8	AA3R_HUMAN		Ki	5.49	CHEMBL
Nuclear receptor subfamily 1 group I member 2	Nuclear hormone receptor	O75469	NR1I2_HUMAN				WOMBAT-PK
ATP-binding cassette sub-family G member 2	Transporter	Q9UNQ0	ABCG2_HUMAN		IC50	4.78	CHEMBL
Cytochrome P450 2C9	Enzyme	P11712	CP2C9_HUMAN		IC50	6.55	WOMBAT-PK
Voltage-dependent T-type calcium channel subunit alpha-1H	Ion channel	O95180	CAC1H_HUMAN		Ki	5.55	WOMBAT-PK
Malate dehydrogenase cytoplasmic	Enzyme	P40925	MDHC_HUMAN		IC50	4.30	CHEMBL
Cytochrome P450 3A4	Enzyme	P08684	CP3A4_HUMAN		IC50	6.38	WOMBAT-PK
Beta-lactamase	Enzyme		AMPC_ECOLI		IC50	4.70	CHEMBL
Adenosine receptor A1	GPCR		AA1R_RAT		Ki	4.71	CHEMBL
Adenosine receptor A2a	GPCR		AA2AR_RAT		Ki	4.20	CHEMBL
Adenosine receptor A3	GPCR		AA3R_RAT		Ki	4.96	CHEMBL
Equilibrative nucleoside transporter 1	Transporter		S29A1_RAT		Ki	5.27	CHEMBL
Quinolone resistance protein NorA	Transporter		NORA_STAAU		IC50	4.64	CHEMBL
Adrenergic receptor alpha-2	GPCR		ADA2B_RAT ADA2C_RAT ADA2A_RAT		IC50	5.85	CHEMBL
Adrenergic receptor alpha-1	GPCR		ADA1B_RAT ADA1D_RAT ADA1A_RAT		IC50	5.44	CHEMBL
Voltage-gated L-type calcium channel	Ion channel		CAC1C_RAT CAC1D_RAT CAC1S_RAT		Ki	9.08	CHEMBL
Potassium voltage-gated channel subfamily A member 4	Ion channel		KCNA4_RAT	BLOCKER	IC50	6.10	IUPHAR

External reference:

ID	Source
4019858	VUID
N0000147944	NUI
D00617	KEGG_DRUG
54527-84-3	SECONDARY_CAS_RN
4019350	VANDF
4019858	VANDF
C0028005	UMLSCUI
CHEBI:7550	CHEBI
CHEMBL1484	ChEMBL_ID
CHEMBL1200326	ChEMBL_ID
D009529	MESH_DESCRIPTOR_UI
DB00622	DRUGBANK_ID
2559	IUPHAR_LIGAND_ID
4745	INN_ID
CZ5312222S	UNII
4474	PUBCHEM_CID
235230	RXNORM
2278	MMSL
5171	MMSL
d00315	MMSL
000712	NDDF
004518	NDDF
108526002	SNOMEDCT_US
108527006	SNOMEDCT_US
372502001	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Nicardipine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9542	INJECTION	2.50 mg	INTRAVENOUS	NDA	26 sections
Nicardipine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9542	INJECTION	2.50 mg	INTRAVENOUS	NDA	26 sections
Nicardipine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9593	INJECTION	2.50 mg	INTRAVENOUS	NDA	26 sections
Nicardipine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9633	INJECTION	0.20 mg	INTRAVENOUS	NDA	27 sections
Nicardipine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9633	INJECTION	0.20 mg	INTRAVENOUS	NDA	27 sections
Nicardipine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9634	INJECTION	0.10 mg	INTRAVENOUS	NDA	27 sections
Nicardipine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9634	INJECTION	0.10 mg	INTRAVENOUS	NDA	27 sections
Nicardipine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9689	INJECTION	25 mg	INTRAVENOUS	NDA	27 sections
Nicardipine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9689	INJECTION	25 mg	INTRAVENOUS	NDA	27 sections
Nicardipine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0378-1020	CAPSULE	20 mg	ORAL	ANDA	22 sections
Nicardipine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0378-1430	CAPSULE	30 mg	ORAL	ANDA	22 sections
Nicardipine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0517-0735	INJECTION, SOLUTION	2.50 mg	INTRAVENOUS	ANDA	26 sections
Nicardipine Hydrochloride	Human Prescription Drug Label	1	0781-3204	INJECTION	2.50 mg	INTRAVENOUS	ANDA	12 sections
Nicardipine Hydrochloride	Human Prescription Drug Label	1	0781-9324	INJECTION	2.50 mg	INTRAVENOUS	ANDA	12 sections
Cardene IV	HUMAN PRESCRIPTION DRUG LABEL	1	10122-313	INJECTION, SOLUTION	0.10 mg	INTRAVENOUS	NDA	23 sections
Cardene IV	HUMAN PRESCRIPTION DRUG LABEL	1	10122-314	INJECTION, SOLUTION	0.10 mg	INTRAVENOUS	NDA	23 sections
Cardene IV	HUMAN PRESCRIPTION DRUG LABEL	1	10122-325	INJECTION, SOLUTION	0.20 mg	INTRAVENOUS	NDA	23 sections
Nicardipine Hydrochloride	Human Prescription Drug Label	1	14593-124	INJECTION	2.50 mg	INTRAVENOUS	ANDA	12 sections
Nicardipine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	24658-750	CAPSULE	20 mg	ORAL	ANDA	19 sections
Nicardipine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	24658-751	CAPSULE	30 mg	ORAL	ANDA	19 sections
NICARDIPINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	35573-457	CAPSULE	20 mg	ORAL	ANDA	13 sections
NICARDIPINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	35573-458	CAPSULE	30 mg	ORAL	ANDA	13 sections
Nicardipine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	40042-047	INJECTION, SOLUTION	2.50 mg	INTRAVENOUS	ANDA	20 sections
Nicardipine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	42806-501	CAPSULE	20 mg	ORAL	ANDA	19 sections
Nicardipine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	42806-502	CAPSULE	30 mg	ORAL	ANDA	19 sections
CARDENE IV	HUMAN PRESCRIPTION DRUG LABEL	1	43066-009	INJECTION, SOLUTION	0.10 mg	INTRAVENOUS	NDA	24 sections
CARDENE IV	HUMAN PRESCRIPTION DRUG LABEL	1	43066-009	INJECTION, SOLUTION	0.10 mg	INTRAVENOUS	NDA	24 sections
CARDENE IV	HUMAN PRESCRIPTION DRUG LABEL	1	43066-009	INJECTION, SOLUTION	0.10 mg	INTRAVENOUS	NDA	24 sections
CARDENE IV	HUMAN PRESCRIPTION DRUG LABEL	1	43066-009	INJECTION, SOLUTION	0.10 mg	INTRAVENOUS	NDA	24 sections
CARDENE IV	HUMAN PRESCRIPTION DRUG LABEL	1	43066-016	INJECTION, SOLUTION	0.20 mg	INTRAVENOUS	NDA	24 sections